OOIR: Observatory of International Research

Papers

(The median citation count of Pediatric Blood & Cancer is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Reply to: Comment on: Intravenous iron for critically ill children. Comparison of three dose regimens	825045808
The COVID‐19 pandemic: A rapid global response for children with cancer from SIOP, COG, SIOP‐E, SIOP‐PODC, IPSO, PROS, CCI, and St Jude Global	98
COVID‐19 infection in children and adolescents with cancer in Madrid	89
Osteosarcoma	87
Early advice on managing children with cancer during the COVID‐19 pandemic and a call for sharing experiences	80
How young patients with cancer perceive the COVID‐19 (coronavirus) epidemic in Milan, Italy: Is there room for other fears?	75
Characterization of COVID‐19 disease in pediatric oncology patients: The New York‐New Jersey regional experience	74
Children with cancer in the time of COVID‐19: An 8‐week report from the six pediatric onco‐hematology centers in Lombardia, Italy	71
COVID‐19 and children with cancer: Parents’ experiences, anxieties and support needs	70
COVID‐19 in pediatric oncology from French pediatric oncology and hematology centers: High risk of severe forms?	67
Neuroblastoma	59
Delayed cancer diagnoses and high mortality in children during the COVID‐19 pandemic	58
Hematological manifestations of SARS‐CoV‐2 in children	53
COVID‐19 in pediatric hematopoietic stem cell transplantation: The experience of Spanish Group of Transplant (GETMON/GETH)	50
COVID‐19 anticoagulation recommendations in children	49
The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis	47
2023 ASPHO Conference Paper and Poster Index	46
Clinical presentations and outcomes of children with cancer and COVID‐19: A systematic review	43
COVID‐19 disease in New York City pediatric hematology and oncology patients	42
Impacts of COVID‐19 on caregivers of childhood cancer survivors	40
ABSTRACTS	40
Financial toxicity of childhood cancer and changes to parents’ employment after treatment completion	39
A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high‐grade glioma	39
A collateral effect of the COVID‐19 pandemic: Delayed diagnosis in pediatric solid tumors	38
Single‐center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia	37

Wilms tumor	36
The influence of nutrition on clinical outcomes in children with cancer	36
Pathology of childhood rhabdomyosarcoma: A consensus opinion document from the Children's Oncology Group, European Paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studi	36
Ewing sarcoma	35
An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials	35
A retrospective analysis of recurrent pediatric ependymoma reveals extremely poor survival and ineffectiveness of current treatments across central nervous system locations and molecular subgroups	34
2020 ASPHO Conference Paper and Poster Index	34
ABSTRACTS	33
Internet‐delivered insomnia intervention improves sleep and quality of life for adolescent and young adult cancer survivors	32
No increase in psychosocial stress of Dutch children with cancer and their caregivers during the first months of the COVID‐19 pandemic	32
Safety of administration of BNT162b2 mRNA (Pfizer‐BioNTech) COVID‐19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG‐asparaginase	32
Convalescent plasma for pediatric patients with SARS‐CoV‐2‐associated acute respiratory distress syndrome	32
Children and young adults hospitalized for severe COVID‐19 exhibit thrombotic coagulopathy	32
ORAL ABSTRACTS	31
Late effects of radiation therapy in pediatric patients and survivorship	31
Rare non‐Hodgkin lymphoma of childhood and adolescence: A consensus diagnostic and therapeutic approach to pediatric‐type follicular lymphoma, marginal zone lymphoma, and nonanaplastic peripheral T‐ce	31
SIOP ABSTRACTS	30
Initial report on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARS‐CoV‐2 pandemic	30
COVID‐19 presenting with autoimmune hemolytic anemia in the setting of underlying immune dysregulation	29
A prospective study on the long‐term outcome of prepubertal and pubertal boys undergoing testicular biopsy for fertility preservation prior to hematologic stem cell transplantation	29
Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B‐acute lymphoblastic leukemia	29
A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high‐risk neuroblastoma: An International Neuroblastoma Risk Group project	29
SARS‐CoV‐2 infection in two pediatric patients with immune cytopenias: A single institution experience during the pandemic	28
Are children with SARS‐CoV‐2 infection at high risk for thrombosis? Viscoelastic testing and coagulation profiles in a case series of pediatric patients	27
Area deprivation is associated with poorer overall survival in children with acute lymphoblastic leukemia	26
The importance of age as prognostic factor for the outcome of patients with hepatoblastoma: Analysis from the Children's Hepatic tumors International Collaboration (CHIC) database	26
Severe adverse events during sirolimus “off‐label” therapy for vascular anomalies	26
Collateral effects of COVID‐19 pandemic in pediatric hematooncology: Fatalities caused by diagnostic delay	26
Identification of prognostic factors in childhood T‐cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05‐001 and 11‐001	25
SIOP ABSTRACTS	25
The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project	25
COVID‐19 in pediatric cancer patients in a resource‐limited setting: National data from Peru	25
Sarcopenia is a prognostic outcome marker in children with high‐risk hepatoblastoma	24
Barriers and enablers to physical activity and aerobic fitness deficits among childhood cancer survivors	24
Pediatric cancer research: Surviving COVID‐19	24
Long‐term renal function after treatment for unilateral, nonsyndromic Wilms tumor. A report from the St. Jude Lifetime Cohort Study	24
Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial	24
The gut microbiome in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation	24
Frequency of face touching with and without a mask in pediatric hematology/oncology health care professionals	23
A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC‐042)	23
Improvement of overall survival in the Collaborative Wilms Tumour Africa Project	23
Sickle cell disease and COVID‐19: Susceptibility and severity	23
PediCARE: Development of a poverty‐targeted intervention for pediatric cancer	23
The role of diffusion tensor imaging metrics in the discrimination between cerebellar medulloblastoma and brainstem glioma	23
Second tumor risk in children treated with proton therapy	23
Tools to guide the identification and implementation of care consistent with the psychosocial Standards of care	23
VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma	23
Acute lymphoblastic leukemia	22
Guidance regarding COVID‐19 for survivors of childhood, adolescent, and young adult cancer: A statement from the International Late Effects of Childhood Cancer Guideline Harmonization Group	22
Naxitamab combined with granulocyte‐macrophage colony‐stimulating factor as consolidation for high‐risk neuroblastoma patients in complete remission	21

Homestead together: Pediatric palliative care telehealth support for rural children with cancer during home‐based end‐of‐life care	21
How we approach the diagnosis and management of complex lymphatic anomalies	21
Brain tumors: Medulloblastoma, ATRT, ependymoma	21
Benign course of SARS‐CoV‐2 infection in a series of pediatric oncology patients	20
Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors	20
Delayed presentations of pediatric solid tumors at a tertiary care hospital in the Bronx due to COVID‐19	20
How we approach thrombosis risk in children with COVID‐19 infection and MIS‐C	20
COVID‐19 infection in children with cancer and stem cell transplant recipients in Turkey: A nationwide study	20
Clinical strategies for treating pediatric cancer during the outbreak of 2019 novel coronavirus infection	19
Feasibility of FitSurvivor: A technology‐enhanced group‐based fitness intervention for adolescent and young adult survivors of childhood cancer	19
Long‐term health‐related quality of life in young childhood cancer survivors and their parents	19
Virtual visits as long‐term follow‐up care for childhood cancer survivors: Patient and provider satisfaction during the COVID‐19 pandemic	19
Primary caregiver decision‐making in hematopoietic cell transplantation and gene therapy for sickle cell disease	19
Outcomes of pediatric patients with oncologic disease or following hematopoietic stem cell transplant supported on extracorporeal membrane oxygenation: The PEDECOR experience	19
Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years	19
Rhabdomyosarcoma associated with germline TP53 alteration in children and adolescents: The French experience	19
Surgical management of paratesticular rhabdomyosarcoma: A consensus opinion from the Children's Oncology Group, European paediatric Soft tissue sarcoma Study Group, and the Cooperative Weichteilsarkom	18
Rhabdomyosarcoma	18
Long‐term cognitive and academic outcomes among pediatric brain tumor survivors treated with proton versus photon radiotherapy	18
Administrative data identify sickle cell disease: A critical review of approaches in U.S. health services research	18
Why do young people get cancer?	18
Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group	18
Kaposiform lymphangiomatosis treated with multimodal therapy improves coagulopathy and reduces blood angiopoietin‐2 levels	17
Outcome at the end of treatment of patients with common and curable childhood cancer types in Blantyre, Malawi	17
Discrepancies between F‐18‐FDG PET/CT findings and conventional imaging in Langerhans cell histiocytosis	17
¹⁸F‐FDG PET and PET/CT as a diagnostic method for Ewing sarcoma: A systematic review and meta‐analysis	17
Clinical prognostic factors in pediatric adrenocortical tumors: A meta‐analysis	17
Bevacizumab for NF2‐associated vestibular schwannomas of childhood and adolescence	17
A randomized controlled trial of a structured exercise intervention after the completion of acute cancer treatment in adolescents and young adults	17
Can recombinant technology address asparaginase Erwinia chrysanthemi shortages?	17
FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma	17
TIM‐3 deficiency presenting with two clonally unrelated episodes of mesenteric and subcutaneous panniculitis‐like T‐cell lymphoma and hemophagocytic lymphohistiocytosis	17
Ruxolitinib in children with steroid‐refractory acute graft‐versus‐host disease: A retrospective multicenter study of the pediatric group of SFGM‐TC	17
Local treatment of rhabdomyosarcoma of the female genital tract: Expert consensus from the Children's Oncology Group, the European Soft‐Tissue Sarcoma Group, and the Cooperative Weichteilsarkom Studie	16
If only I could turn back time—Regret in bereaved parents	16
A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pedia	16
Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab	16
COVID‐19 and childhood acute lymphoblastic leukemia	16
Household material hardships impact emergency department reliance in pediatric patients with sickle cell disease	16
Implementation of daily patient‐reported outcome measurements to support children with cancer	16
Impact of COVID‐19 on adolescent and emerging adult brain tumor survivors and their parents	16
Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy–induced vomiting in children: An open‐label, randomized phase 3 trial	16
Whole‐body magnetic resonance imaging as surveillance for subsequent malignancies in preadolescent, adolescent, and young adult survivors of germline retinoblastoma: An update	16
Treatment of acute myeloid leukemia in children: A practical perspective	16
A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low‐grade glioma	16
COVID‐19 infection in febrile neutropenic pediatric hematology oncology patients	16
A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase‐Clinical Trial Network (PEP‐CTN)	16
Care experiences that foster trust between parents and physicians of children with cancer	16
The role of interferon‐gamma and its signaling pathway in pediatric hematological disorders	16
A community‐based trial of a psychosocial eHealth intervention for parents of children with cancer	15
Introducing INSTRuCT: An international effort to promote cooperation and data sharing	15
Severe COVID‐19 disease in two pediatric oncology patients	15
Phase II trial of gemcitabine and nab‐paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer Foundation	15
Evaluation of financial relationships between Japanese certified pediatric hematologist/oncologists and pharmaceutical companies: a cross‐sectional analysis of personal payments from pharmaceutical co	15
Undifferentiated sarcoma of the liver: Multicenter international experience of the Cooperative Soft‐Tissue Sarcoma Group and Polish Paediatric Solid Tumor Group	15
Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B‐cell acute lymphoblastic leukemia	15
Assessment of nutritional status in children with cancer: Significance of arm anthropometry and serum visceral proteins	15
SARS‐CoV‐2 disease and children under treatment for cancer	15
Epidemiology and survival of childhood cancer in Turkey	15
Autologous stem cell transplant for high‐risk neuroblastoma: Achieving cure with low‐cost adaptations	15
Adrenocortical tumours in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations	15
Mucosal barrier injury–associated bloodstream infections in pediatric oncology patients	15
Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma	15
Acute chest syndrome in the setting of SARS‐COV‐2 infections—A case series at an urban medical center in the Bronx	15
Treatment of central giant cell granuloma in children with denosumab	15
Clinical outcomes and quality of life in children and adolescents with primary brain tumors treated with pencil beam scanning proton therapy	15
A Saudi family with sickle cell disease presented with acute crises and COVID‐19 infection	15
A review of the experience with pediatric written requests issued for oncology drug products	15
Oncology care in a lower middle‐income country during the COVID‐19 pandemic	14
Pseudohypoxic pheochromocytomas and paragangliomas dominate in children	14
Effects of hydroxyurea on brain function in children with sickle cell anemia	14
Pancreaticoduodenectomy for the treatment of pancreatic neoplasms in children: A Pediatric Surgical Oncology Research Collaborative study	14
Radiogenomics prediction for MYCN amplification in neuroblastoma: A hypothesis generating study	14
A safety and feasibility trial of ¹³¹I‐MIBG in newly diagnosed high‐risk neuroblastoma: A Children's Oncology Group study	14
Screening for SARS‐CoV‐2 infection in pediatric oncology patients during the epidemic peak in Italy	14
Clinical heterogeneity of pediatric hepatocellular carcinoma	14
The importance of enteral nutrition to prevent or treat undernutrition in children undergoing treatment for cancer	14
Impact of Medicaid expansion on access and healthcare among individuals with sickle cell disease	14
Critical illness epidemiology and mortality risk in pediatric oncology	14
The role of twinning in sustainable care for children with cancer: A TIPPing point? SIOP PODC Working Group on Twinning, Collaboration, and Support	14

Safety and efficacy of gamma‐secretase inhibitor nirogacestat (PF‐03084014) in desmoid tumor: Report of four pediatric/young adult cases	14
Palliative care considerations and practices for adolescents and young adults with cancer	14
Delivering pediatric oncology services during a COVID‐19 pandemic in India	14
Pediatric hematology and oncology fellow education in sexual and reproductive health: A survey of fellowship program directors in the United States	14
Factors affecting COVID‐19 vaccine hesitancy in parents of children with cancer	13
Treatment of generalized infantile myofibromatosis with sorafenib and imatinib: A case report	13
Much is left unspoken: Self‐reports from families in pediatric oncology	13
COVID‐19 and childhood acute lymphoblastic leukemia	13
How we approach malignant infantile osteopetrosis	13
Abstracts for PBC Volume 67, Supplement 5	13
Defining palliative opportunities in pediatric patients with bone and soft tissue sarcomas	13
Role of bone marrow biopsy for staging new patients with Ewing sarcoma: A systematic review	13
Impact of insurance type and timing of Medicaid enrollment on survival among adolescents and young adults with cancer	13
Different ¹⁸F‐FDG PET parameters for the prediction of histological response to neoadjuvant chemotherapy in pediatric Ewing sarcoma family of tumors	13
Acute lymphoblastic leukemia onset in a 3‐year‐old child with COVID‐19	13
Successful use of transarterial radioembolization with yttrium‐90 (TARE‐Y90) in two children with hepatoblastoma	13
Autoimmune cytopenias following allogeneic hematopoietic stem cell transplant in pediatric patients: Response to therapy and late effects	13
Alveolar rhabdomyosarcoma with regional nodal involvement: Results of a combined analysis from two cooperative groups	13
“Living life as if I never had cancer”: A study of the meaning of living well in adolescents and young adults who have experienced cancer	13
The use of interval‐compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor	13
Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate‐risk Hodgkin lymphoma treated with chemo‐radiation therapy: FDG‐PET parameter analysis in a subgroup f	13
Citrulline as a biomarker of bacteraemia during induction treatment for childhood acute lymphoblastic leukaemia	13
Interdependent functions of communication with adolescents and young adults in oncology	13
Recognizing and managing hereditary and acquired thrombotic thrombocytopenic purpura in infants and children	13
miRNA expression can classify pediatric thyroid lesions and increases the diagnostic yield of mutation testing	13
Hyperglycemia requiring insulin during acute lymphoblastic leukemia induction chemotherapy is associated with increased adverse outcomes and healthcare costs	13
The state of the science for communication training in pediatric oncology: A systematic review	13
In vivo evaluation of the lysine‐specific demethylase (KDM1A/LSD1) inhibitor SP‐2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consor	13
A pilot trial of prophylactic defibrotide to prevent serious thrombotic microangiopathy in high‐risk pediatric patients	13
Diverse populations and enrollment in pediatric cancer clinical trials: Challenges and opportunities	12
Paratesticular rhabdomyosarcoma—Impact of locoregional approach on patient outcome: A report from the European paediatric Soft tissue sarcoma Study Group (EpSSG)	12
“Money was the problem”: Caregivers' self‐reported reasons for abandoning their children's cancer treatment in southwest Uganda	12
Reducing acute kidney injury in pediatric oncology patients: An improvement project targeting nephrotoxic medications	12
Diagnosis and treatment of pediatric myelodysplastic syndromes: A survey of the North American Pediatric Aplastic Anemia Consortium	12
Psychological adjustment outcomes among pediatric brain tumor survivors: A meta‐analysis	12
Consensus recommendations from the EXPeRT/PARTNER groups for the diagnosis and therapy of sex cord stromal tumors in children and adolescents	12
Congenital neutropenia with variable clinical presentation in novel mutation of the SRP54 gene	12
Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib	12
Clinical evaluation of late outcomes in Dutch childhood cancer survivors: Methodology of the DCCSS LATER 2 study	12
Pheochromocytomas and paragangliomas in children: Data from the Italian Cooperative Study (TREP)	12
Surgical management of extremity rhabdomyosarcoma: A consensus opinion from the Children's Oncology Group, the European Pediatric Soft‐Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom S	12
Clinical, pathologic, and molecular features of inflammatory myofibroblastic tumors in children and adolescents	12
A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib	12
Evaluation of the nephron‐sparing surgery formula in Wilms tumors	12
L‐leucine improves anemia and growth in patients with transfusion‐dependent Diamond‐Blackfan anemia: Results from a multicenter pilot phase I/II study from the Diamond‐Blackfan Anemia Registry	12
SARS‐CoV‐2 in children with cancer in Brazil: Results of a multicenter national registry	12
Intravenous ferric carboxymaltose for iron deficiency anemia or iron deficiency without anemia after poor response to oral iron treatment: Benefits and risks in a cohort of 144 children and adolescent	12
Prevention and treatment of anticipatory chemotherapy‐induced nausea and vomiting in pediatric cancer patients and hematopoietic stem cell recipients: Clinical practice guideline update	12
Allopurinol use during pediatric acute lymphoblastic leukemia maintenance therapy safely corrects skewed 6‐mercaptopurine metabolism, improving inadequate myelosuppression and reducing gastrointestina	12
Clinical impact of hypothalamic‐pituitary disorders after conformal radiation therapy for pediatric low‐grade glioma or ependymoma	12
A pilot study of the preliminary efficacy of Pain Buddy: A novel intervention for the management of children's cancer‐related pain	12
Pleuropulmonary blastoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations	12
Family functioning and adaptation following pediatric brain tumor: A systematic review	12
Radiologic response to MEK inhibition in a patient with a WNT‐activated craniopharyngioma	12
Solitary serum methotrexate level 36 hours post high‐dose methotrexate: A safe, efficacious, and cost‐effective strategy to monitor methotrexate toxicities in childhood leukemia in resource‐limited ce	12
The annual incidence of Langerhans cell histiocytosis among adults living in Greece	12
Racial and ethnic disparities in survival of children with brain and central nervous tumors in the United States	12
Physical activity for children undergoing acute cancer treatment: A qualitative study of parental perspectives	12
Implementing newborn screening for sickle cell disease in Korle Bu Teaching Hospital, Accra: Results and lessons learned	12
Incidence and 5‐year survival of children and adolescents with hepatoblastoma in the United States	12
Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity	11
Dermatofibrosarcoma protuberans in children and adolescents: The European Paediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005)	11
Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma	11
Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study	11
Cranial polyneuropathy as the first manifestation of a severe COVID‐19 in a child	11
Prospective randomized trial of interventions for vincristine‐related neuropathic pain	11
The COVID‐19 pandemic: Distance‐delivered care for childhood cancer survivors	11
Nocturnal hypertension associated with stroke and silent cerebral infarcts in children with sickle cell disease	11
Treatment abandonment: A report from the collaborative African network for childhood cancer care and research—CANCaRe Africa	11
Practice patterns and recommendations for pediatric image‐guided radiotherapy: A Children's Oncology Group report	11
Fathers' psychological responses to pediatric cancer–induced financial distress	11
Multicystic and diffuse malignant peritoneal mesothelioma in children	11
Pediatric and young adult renal cell carcinoma	11
Socioeconomic disparities in survival after high‐risk neuroblastoma treatment with modern therapy	11
Children with cancer during COVID‐19 pandemic: Early experience in Mexico	11
Prevention of acute and delayed chemotherapy‐induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline	11
Health support to pediatric cancer survivors and their families during the COVID‐19 pandemic	11
Abstracts from the 38^th Annual Meeting of the Histiocyte Society Held Virtually and In Person in Stockholm, Sweden from September 18‐20, 2022	11
Pineoblastoma in children less than six years of age: The Head Start I, II, and III experience	11
Oral processing speed as a key mechanism in the relationship between neurological risk and adaptive functioning in survivors of pediatric brain tumors	11
Hematological parameters and peripheral blood morphologic abnormalities in children with COVID‐19	11
Consequences of hemophagocytic lymphohistiocytosis‐like cytokine release syndrome toxicities and concurrent bacteremia	11
Extraskeletal Ewing sarcoma in children, adolescents, and young adults. An analysis of three prospective studies of the Cooperative Weichteilsarkomstudiengruppe (CWS)	11
Unresectable thoracic neuroblastic tumors: Changes in image‐defined risk factors after chemotherapy and impact on surgical management	11
A single supratentorial high‐grade neuroepithelial tumor with two distinct BCOR mutations, exceptionally long complete remission and survival	11
Nutritional traditional and complementary medicine strategies in pediatric cancer: A narrative review	11
Social determinants of health and pediatric cancer survival: A systematic review	11
Unsatisfactory quality of E. coli asparaginase biogenerics in India: Implications for clinical outcomes in acute lymphoblastic leukaemia	11
Comparison of neuropsychological functioning in pediatric posterior fossa tumor survivors: Medulloblastoma, low‐grade astrocytoma, and healthy controls	11
The intersectionality of gender and poverty on symptom suffering among adolescents with cancer	11
Association of fludarabin, cytarabine, and fractioned gemtuzumab followed by hematopoietic stem cell transplantation for first‐line refractory acute myeloid leukemia in children: A single‐center exper	11
A study assessing the feasibility of randomization of pediatric and young adult patients between matched unrelated donor bone marrow transplantation and immune‐suppressive therapy for newly diagnosed	11
Acceptability and feasibility of survivorship care plans and an accompanying mobile health intervention for adolescent and young adult survivors of childhood cancer	11
Management of pediatric differentiated thyroid cancer: An overview for the pediatric oncologist	11
Long‐term outcomes of children with extracutaneous juvenile xanthogranulomas in Japan	11